Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCVax in Chronic Hepatitis C
NCT04318379Phase 1Unknown
- Sponsor
- GeneCure Biotechnologies
- Start
- Apr 2021
- Primary completion
- Feb 2023
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of HCVax in hepatitis C (HCV) (2 arms), sponsored by GeneCure Biotechnologies. Primary endpoint: Safety of a therapeutic HCV vaccine in chronic HCV patients at 40 weeks. Status: unknown.
02
Drugs
HCVax
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04318379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04318379.